

A ubiquitin-independent proteasome pathway controls activation of the CARD8 inflammasome

Jeffrey C. Hsiao, Atara R. Neugroschl, Ashley J. Chui, Cornelius Y. Taabuzing, Andrew R. Griswold, Qinghui Wang, Hsin-Che Huang, Elizabeth L. Orth-He, Daniel P. Ball, Giorgos Hiotis, & Daniel A. Bachovchin*

*Correspondence: bachovcd@mskcc.org

This PDF file includes:
Figures S1 and its Figure Legend

Figure S1




Figure S1. Characterization of CARD8 lysine mutants. (A) HEK 293T cells were transiently transfected with the indicated plasmid constructs prior to immunoblotting analyses. It should be noted that the laddering of the CT protein is likely due to incomplete dissociation of its oligomers by the sample preparation procedure for SDS-PAGE. (B) HEK 293T cells were transiently transfected with the indicated constructs. Lysates were harvested and HA-tagged proteins were enriched. The input and elution fractions were analyzed by immunoblotting. The CARD8 E274R mutation renders it unable to bind to DPP8/9. (C) HEK 293T^{CASP1+GSDMD} cells were transfected with plasmids encoding the indicated plasmids. After 24 h, cells were treated with dTAG-13 for 5 h before immunoblotting analyses. (D) *CARD8*^{-/-} THP-1 cells stably expressing *CARD8*^{FL} K10R were treated with the indicated compounds for 8 hours prior to LDH release and immunoblotting analyses. (E) A tet-on plasmid encoding *CARD8*^{FL} S297A was transfected into HEK 293T cells. After 20 h, cells were co-treated with the indicated drugs for 24 h before lysates were analyzed by immunoblotting. The densitometry ratio of *CARD8*^{p44} to *CARD8*^{FL} was quantified for each treatment group. Data in (E) (n=3) are means ± standard deviation (SD) of replicates. ** $p = 0.0085$ by Student's two-sided *t*-test. All immunoblots are representative of 3 or more independent experiments.